Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study

Patients with locally advanced esophageal squamous cell carcinoma (ESCC) show poor survival after concurrent chemoradiotherapy. This study investigated the safety and feasibility of combining concurrent chemoradiotherapy with the anti-PD-1 antibody camrelizumab as first-line treatment for these pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wencheng, Yan, Cihui, Zhang, Tian, Chen, Xi, Dong, Jie, Zhao, Jingjing, Han, Dong, Wang, Jun, Zhao, Gang, Cao, Fuliang, Zhou, Dejun, Jiang, Hongjing, Tang, Peng, Zhao, Lujun, Yuan, Zhiyong, Wang, Quanren, Wang, Ping, Pang, Qingsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489938/
https://www.ncbi.nlm.nih.gov/pubmed/34616588
http://dx.doi.org/10.1080/2162402X.2021.1971418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489938/
https://www.ncbi.nlm.nih.gov/pubmed/34616588
http://dx.doi.org/10.1080/2162402X.2021.1971418

Ejemplares similares